Noxxon, Aram Mangasarian: Clinical stage Spiegelmer® therapeutics displaying good safety, tolerability and promising signs of efficacy




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Noxxon, Aram Mangasarian: Clinical stage Spiegelmer® therapeutics displaying good safety, tolerability and promising signs of efficacy
Released on: January 17, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at BIO Europe 2013 in Vienna Aram Mangasarian, Chief Business Officer at Noxxon Pharma talks to Paul Larsmon about pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized, non-immunogenic alternative to antibodies.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at BIO Europe 2013 in Vienna Aram Mangasarian, Chief Business Officer at Noxxon Pharma talks to Paul Larsmon about pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics for the treatment of inflammatory diseases and hematological disorders.
In this interview filmed at BIO Europe 2013 in Vienna Aram Mangasarian, Chief Business Officer at Noxxon Pharma talks to Paul Larsmon about pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics for the treatment of inflammatory diseases and hematological disorders.
Aram Mangasarian
Noxxon
NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics: • Spiegelmer® NOX-E36 • Spiegelmer® NOX-A12 • Spiegelmer® NOX-H94 The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.